Meeting
2017 ASCO Annual Meeting
Activity of RX-3117, an oral antimetabolite nucleoside, in subjects with metastatic bladder cancer resistant to gemcitabine: Preliminary results of a phase Ia/IIb study.
Authors
Jun Gong
City of Hope Comprehensive Cancer Center, Duarte, CA
Jun Gong , Vincent M. Chung , Joel Picus , Scott T. Tagawa , Sumati Gupta , Julie Poore , Christine Peterson , Ely Benaim , Sumanta K. Pal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Clinical Trial Registration Number
NCT02030067
Citation
J Clin Oncol 35, 2017 (suppl; abstr 4544)
DOI
10.1200/JCO.2017.35.15_suppl.4544
Abstract #
4544
Poster Bd #
222
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Assessing the utility of a cell-free tumor (ct)DNA assay (MSK-ACCESS) in patients (pts) with node-positive (N+) muscle-invasive bladder cancer (MIBC) undergoing neoadjuvant chemotherapy (NAC).
First Author: Andrew B Katims
Poster
2024 ASCO Genitourinary Cancers Symposium
Real world experience of FGFR gene alterations and clinical outcomes in advanced/metastatic urothelial cancer in Japan: MONSTAR-SCREEN database study.
First Author: Nobuaki Matsubara
Poster
2022 ASCO Genitourinary Cancers Symposium
Novel use of ctDNA to identify locally advanced and metastatic upper tract urothelial carcinoma.
First Author: Heather L. Huelster
Poster
2019 Genitourinary Cancers Symposium
Non-urothelial bladder cancer: Genomic alterations and patient outcomes.
First Author: Fern Anari